Evidence / Evans et al. · 2011
Synthetic genistein in a postmenopausal trial
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Multicentre randomized, double-blind, placebo-controlled human trial.
- Product relevance
- Ingredient evidence from synthetic genistein.
- Sample or population
- 84 postmenopausal women.
- Studied dose
- 30 mg/day of synthetic genistein or placebo.
- Duration
- 12 weeks.
- Finding
- Among analyzed participants, hot-flush frequency and total daily duration were lower with genistein. The abstract reports no between-group differences in several hormonal and endometrial measures or adverse events.
- Limitations
- The reported analyses use participant subsets. The trial does not establish long-term safety or effects of soybean-derived genistein in a combination.
- Study quality
- Placebo-controlled design with analyses based on time on trial. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.